Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules.
暂无分享,去创建一个
X. Montalban | J. Río | N. Barbera | E. Martínez-Cáceres | M. E. Marzo | I. Durán | José Antonio del Río | Xavier Montalban | X. Montalban
[1] Cathy J. Price,et al. Functional anatomy of reading , 2003 .
[2] C. Price,et al. Three Distinct Ventral Occipitotemporal Regions for Reading and Object Naming , 1999, NeuroImage.
[3] F. Barkhof,et al. Primary and transitional progressive MS , 1999, Neurology.
[4] G. McDonnell,et al. Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease , 1999, Journal of Neurology.
[5] M. Pender,et al. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis , 1998, Annals of neurology.
[6] C. Price. The functional anatomy of word comprehension and production , 1998, Trends in Cognitive Sciences.
[7] G. McDonnell,et al. Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis , 1998, Journal of Neuroimmunology.
[8] M. Jutila,et al. Calmodulin Regulates L-Selectin Adhesion Molecule Expression and Function through a Protease-Dependent Mechanism , 1998, Cell.
[9] R. Rudick,et al. Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.
[10] H. Hartung,et al. Modulation of the expression of integrins on glial cells during experimental autoimmune encephalomyelitis. A central role for TNF-alpha. , 1997, The American journal of pathology.
[11] Karl J. Friston,et al. Human Brain Function , 1997 .
[12] H. Hartung,et al. The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications. , 1997, Molecular medicine today.
[13] A. Thompson,et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis , 1997, Neurology.
[14] A J Thompson,et al. PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS , 1997 .
[15] J. Dambrosia,et al. Increases in soluble VCAM‐1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β‐1b , 1997, Annals of neurology.
[16] R. Hohlfeld,et al. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. , 1997, Brain : a journal of neurology.
[17] Karl J. Friston,et al. Cognitive Conjunction: A New Approach to Brain Activation Experiments , 1997, NeuroImage.
[18] R. Bergamaschi,et al. Soluble CD8 and ICAM‐1 in serum and CSF of MS patients treated with 6‐methylprednisolone , 1997, Acta neurologica Scandinavica.
[19] G. Grau,et al. Brain microvascular endothelial cells and leukocytes derived from patients with multiple sclerosis exhibit increased adhesion capacity , 1997, Neuroreport.
[20] R. Salonen,et al. Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis , 1997, Journal of Neuroimmunology.
[21] M. Trojano,et al. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis , 1996, Neurology.
[22] J. Hodges,et al. Generating ‘tiger’ as an animal name or a word beginning with T: differences in brain activation , 1996, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[23] Moses Rodriguez,et al. Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis , 1996, Brain pathology.
[24] H. McFarland,et al. Expression pattern of activation and adhesion molecules on peripheral blood CD4+ T-lymphocytes in relapsing-remitting multiple sclerosis patients: a serial analysis , 1996, Journal of Neuroimmunology.
[25] A. Lentsch,et al. The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice. , 1996, The Journal of clinical investigation.
[26] L. Picker,et al. Lymphocyte Homing and Homeostasis , 1996, Science.
[27] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[28] J. Goding,et al. Monoclonal Antibodies: Principles and Practice , 1996 .
[29] Richard S. J. Frackowiak,et al. Noun and verb retrieval by normal subjects. Studies with PET. , 1996, Brain : a journal of neurology.
[30] X. Montalban,et al. Different antiganglioside antibody pattern between relapsing‐remitting and progressive multiple sclerosis , 1996, Acta neurologica Scandinavica.
[31] A. Thompson,et al. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[32] T. Nurmikko,et al. CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis , 1995, Acta Neurologica Scandinavica.
[33] Y. Ron,et al. Bothanti-CD11a(LFA-l) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis , 1995, Journal of Neuroimmunology.
[34] M. Miyasaka,et al. Antibodies against leukocyte function-associated antigen-1 and against intercellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis. , 1995, Cellular immunology.
[35] H. Hartung,et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: Correlation with magnetic resonance imaging , 1995, Annals of neurology.
[36] N. Yanagisawa,et al. Increased levels of soluble vascular cell adhesion molecule-1 ( VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy , 1995, Journal of Neuroimmunology.
[37] Judith E. Cartwright,et al. The expression and release of adhesion molecules by human endothelial cell lines and their consequent binding of lymphocytes. , 1995, Experimental cell research.
[38] J. Alberola-Ila,et al. Existence of a soluble form of CD50 (intercellular adhesion molecule-3) produced upon human lymphocyte activation. Present in normal human serum and levels are increased in the serum of systemic lupus erythematosus patients. , 1995, Journal of immunology.
[39] S. Martin,et al. Circulating forms of ICAM-3 (cICAM-3). Elevated levels in autoimmune diseases and lack of association with cICAM-1. , 1995, Journal of immunology.
[40] M. Peterson,et al. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: Correlation with clinical activity , 1995, Annals of neurology.
[41] A. Broocks,et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients a with multinle sclerosis , 1994, Neurology.
[42] J. Olschowka,et al. Expression of ICAM-1, VCAM-1, L-selectin, and leukosialin in the mouse central nervous system during the induction and remission stages of experimental allergic encephalomyelitis , 1994, Journal of Neuroimmunology.
[43] A J Thompson,et al. A comparison of the pathology of primary and secondary progressive multiple sclerosis. , 1994, Brain : a journal of neurology.
[44] B. Engelhardt,et al. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. , 1994, The American journal of pathology.
[45] T. Springer. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.
[46] V. Kuchroo,et al. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. , 1993, Journal of immunology.
[47] A. Gearing,et al. Circulating adhesion molecules in disease. , 1993, Immunology today.
[48] G. Hansson,et al. Adhesion molecule expression on cerebrospinal fluid T lymphocytes: Evidence for common recruitment mechanisms in multiple sclerosis, aseptic meningitis, and normal controls , 1993, Annals of neurology.
[49] H. Kolb,et al. Elevated Levels of Circulating Adhesion Molecules in IDDM Patients and in Subjects at Risk for IDDM , 1992, Diabetes.
[50] F. Sánchez‐Madrid,et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin , 1992, Nature.
[51] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[52] H. Lassmann. Basic mechanisms of brain inflammation. , 1997, Journal of neural transmission. Supplementum.
[53] J. Goding. 8 – Production of Monoclonal Antibodies , 1996 .
[54] R. Todd Constable,et al. Localization of semantic processing using functional magnetic resonance imaging , 1994 .
[55] S. Petersen,et al. Practice-related changes in human brain functional anatomy during nonmotor learning. , 1994, Cerebral cortex.